Everything below concerns Ac-SDKP. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-02-07. Numbers and descriptions here follow the published literature rather than marketing material.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Acanthaster planci, starfish (2014) Apostichopus japonicus, sea cucumber (2017) Arbacia lixula, black sea urchin (2024) Astropecten irregularis, sand sea star (2024) Australostichopus mollis, Australian sea cucumber (2016) Chiridota hydrothermica, deep sea cucumber (2024) Diadema setosum, Long-spined sea urchin (2024) Echinometra lucunter, rock boring urchin (2023) Ophionereis fasciata, mottled brittlestar (2016) Patiriella regularis, the New Zealand common cushion star (2016) Plazaster borealis, Octopus starfish (2022) Strongylocentrotus purpuratus, a sea urchin and model deuterostome (2006)
Brain failure after clinical death is now known to be due to a complex series of processes called reperfusion injury that occur after blood circulation has been restored, especially processes that interfere with blood circulation during the recovery period. Control of these processes is the subject of ongoing research. In 1990, the laboratory of resuscitation pioneer Peter Safar discovered that reducing body temperature by three degrees Celsius after restarting blood circulation could double the time window of recovery from clinical death without brain damage from 5 minutes to 10 minutes. This induced hypothermia technique is beginning to be used in emergency medicine. The combination of mildly reducing body temperature, reducing blood cell concentration, and increasing blood pressure after resuscitation was found especially effective – allowing for recovery of dogs after 12 minutes of clinical death at normal body temperature with practically no brain injury. The addition of a drug treatment protocol has been reported to allow recovery of dogs after 16 minutes of clinical death at normal body temperature with no lasting brain injury. Cooling treatment alone has permitted recovery after 17 minutes of clinical death at normal temperature, but with brain injury. Under laboratory conditions at normal body temperature, the longest period of clinical death of a cat (after complete circulatory arrest) survived with eventual return of brain function is one hour.
Biochemistry is the study of the chemical substances and vital processes occurring in live organisms. Biochemists focus heavily on the role, function, and structure of bio-molecules. The study of the chemistry behind biological processes and the synthesis of biologically active molecules are applications of biochemistry. Biochemistry studies life at the atomic and molecular level. Genetics is the study of the effect of genetic differences in organisms. This can often be inferred by the absence of a normal component (e.g. one gene). The study of "mutants" – organisms that lack one or more functional components with respect to the so-called "wild type" or normal phenotype. Genetic interactions (epistasis) can often confound simple interpretations of such "knockout" studies. Molecular biology is the study of molecular underpinnings of the biological phenomena, focusing on molecular synthesis, modification, mechanisms and interactions. The central dogma of molecular biology, where genetic material is transcribed into RNA and then translated into protein, despite being oversimplified, still provides a good starting point for understanding the field. This concept has been revised in light of emerging novel roles for RNA. Chemical biology seeks to develop new tools based on small molecules that allow minimal perturbation of biological systems while providing detailed information about their function.
Dupuytren's contracture (also called Dupuytren's disease, Morbus Dupuytren, Palmar fibromatosis and colloquially Viking disease, Viking hand or Celtic hand) is a condition in which one or more fingers become permanently bent in a flexed position. It is named after Guillaume Dupuytren, who first described the underlying mechanism of action, followed by the first successful operation in 1831 and publication of the results in The Lancet in 1834. It usually begins as small, hard nodules just under the skin of the palm, then worsens over time until the fingers can no longer be fully straightened. While typically not painful, some aching or itching, or pain, may be present. The ring finger followed by the little and middle fingers are most commonly affected. It can affect one or both hands. The condition can interfere with activities such as preparing food, writing, putting the hand in a tight pocket, putting on gloves, or shaking hands. The causes of Dupuytren's contracture are not completely understood. The disease is driven by over-activation of fibroblasts and myofibroblasts in response to signaling molecules including IL-1 beta, TGF-beta, EGF, and CTGF, leading to inappropriately increased formation of fibrous connective tissue. Risk factors include family history, smoking, thyroid problems, liver disease, diabetes, previous hand trauma, and epilepsy. The development of Dupuytren disease has also been associated with environmental factors, including smoking, alcohol consumption, aging, trauma, and repetitive use of the hand in certain physical occupations.
As of 2024, only one study has directly examined ancient Israelite genetic material. The analysis examined First Temple-era skeletal remains excavated in Abu Ghosh, and showed one male individual belonging to the J2 Y-DNA haplogroup, a set of closely related DNA sequences thought to have originated in the Caucasus or Eastern Anatolia, as well as the T1a and H87 mitochondrial DNA haplogroups, the former of which has also been detected among Canaanites, and the latter in Basques, Tunisian Arabs, and Iraqis, suggesting a Mediterranean, Near Eastern, or perhaps Arabian origin. A 2004 study (by Shen et al.) comparing Samaritans to several Jewish populations (including Ashkenazi Jews, Iraqi Jews, Libyan Jews, Moroccan Jews, and Yemenite Jews) found that "the principal components analysis suggested a common ancestry of Samaritan and Jewish patrilineages. Most of the former may be traced back to a common ancestor in what is today identified as the paternally inherited Israelite high priesthood (Cohanim), with a common ancestor projected to the time of the Assyrian conquest of the kingdom of Israel." A 2020 study (by Agranat-Tamr et al.) stated that there was genetic continuity between the Bronze Age and Iron Age southern Levantines, which included the Israelites and Judahites. They could be "modeled as a mixture of local earlier Neolithic populations and populations from the northeastern part of the Near East (e.g. Zagros Mountains, Caucasians/Armenians and possibly, Hurrians)".
Sources: en.wikipedia.org
For example, Gioja (current Gioia Tauro), was fortified with city walls reinforced by watchtowers to defend against incursions. Several Calabrian cities such as Palmi (where the Saracen Tower stands) and Reggio Calabria were fortified with towers. Despite the heavy taxation and the growth of baronial power, the population remained loyal to the sovereign, seen as a defender of the poor people against the abuses of the powerful. In 1647–1648, exasperated by the excessive tax burden, people in Catanzaro stormed the offices of the tax collectors (arrendatori). The governor intervened and had the leaders of the revolt hanged, causing the rest to flee.
On February 19, 2026, Hims & Hers announced an agreement to acquire the Australian digital health company Eucalyptus Health, operator of the Juniper, Pilot, and Kin telehealth brands, for consideration of up to $1.15 billion. Following the completion of the Eucalyptus acquisition, Hims launched in Australia on 1st September 2026, initially offering men's health treatments and weight-loss medication, including branded GLP-1 products. Alongside the launch, the company began retiring Eucalyptus's Pilot men's-health brand and rebranding under the Hims name. The company announced that it would transition existing Pilot clinicians to its platform and plans to introduce women's health services in Australia later in 2026 through their existing Juniper brand.
Hexobarbital or hexobarbitone, sold both in acid and sodium salt forms as Citopan, Evipan, and Tobinal, is a barbiturate derivative having hypnotic and sedative effects. It was used in the 1940s and 1950s as an agent for inducing anesthesia for surgery, as well as a rapid-acting, short-lasting hypnotic for general use, and has a relatively fast onset of effects and short duration of action. Modern barbiturates (such as Thiopental) have largely supplanted the use of hexobarbital as an anesthetic, as they allow for better control of the depth of anesthesia. Hexobarbital is still used in some scientific research.
==== Context ==== The formation of the third cabinet followed the resignation of Mirtha Vásquez on the eve of 31 January 2022. This occurred the day after the resignation of the Minister of the Interior, who resigned citing a “structural problem of corruption” and the impossibility of creating consensus. This decision triggered a political crisis, with the previously supportive Purple Party demanding the formation of a capable government or else the resignation of President Pedro Castillo. The third vice president of the Congress Patricia Chirinos (AvP) announced the filing of a motion of censure against the president, citing the "evident corruption of his government."
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.